

March 6, 2017  
Sysmex Corporation

## Announcement of Organizational and Personnel Changes

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces today its decision to implement organizational and personnel changes, effective April 1, 2017, as detailed below.

These organizational changes include progressively eliminating the business unit structure, as well as reinforcing the business development structure and accelerating strategy deployment in order to achieve further growth.

---

### 1. Organizational Changes

#### (1) Reinforce the business development structure to achieve further growth

- a) Reinforce a highly efficient business development structure in core businesses (the hematology, urinalysis, hemostasis, immunochemistry and clinical chemistry fields)
  - We will newly establish the HU Business Development Division to globally oversee processes from strategic planning to the market launch of products in the hematology and urinalysis fields.  
(HU: The initial letters of hematology and urinalysis)
  - We will newly establish the ICH Business Development Division to globally oversee processes from strategic planning to the market launch of products in the hemostasis, immunochemistry and clinical chemistry fields.  
(ICH: The initial letters of immunochemistry, clinical chemistry and hemostasis)
  - We will newly establish the Engineering 1 Division to handle reagent development in our core businesses.
  - We will newly establish the Engineering 2 Division to handle instrument and system development in our core businesses.
  - These four divisions will arrange appropriate strategy-based projects to foster highly efficient organizational operations featuring coordination and cooperation and to increase business execution speed.
- b) Reinforce the business development structure for our next core businesses (gene testing and other new business domains utilizing proprietary Sysmex technologies)
  - We will newly establish the LS Business Division to globally oversee processes from strategic planning to the market launch of products, and product development in gene testing and lab assay services.  
(LS: life science)
  - We will newly establish the Clinical Innovation Division to establish new clinical value by fostering the rapid market introduction of newly created technologies for research.
  - We will newly establish the MR Business Development Division to promote marketing, sales and services for medical robots.  
(MR: medical robot)
- c) Reinforce the business development structure to create value across fields
  - In addition to performing Group-wide strategic business planning, we will consolidate in the Business Strategy Development Division the global oversight of processes from strategic planning to the market launch of products in the FCM, network solutions, laboratory automation, and research and industry

markets.

- We will establish the Clinical Affairs Department, which plans and designs clinical evaluation tests, within the Scientific Affairs Division in the aim of accelerating regulatory approvals in various countries.

(2) Reinforce the structure to accelerate strategy deployment

a) Strengthen the human resources and general affairs functions

- In line with the expansion of our global business scale, we will newly establish the Human Resources Division to secure human resources who can be active globally, reinforce training and promote diversity.
- In line with an increase in the number of affiliated companies in tandem with our growing scale of business, we will newly establish the General Affairs Division to reinforce global risk management and compliance.

b) Strengthen the R&D support function

- We will newly establish the Technology Strategy Division to promote technology strategy planning for the Group.
- We will newly establish the Intellectual Property Division to enhance the Group's intellectual property functions.

c) Strengthen bio-diagnostic reagent technology development

- We will newly establish the Bio-Diagnostic Reagent Technology Center to handle the development of materials for bio-diagnostic reagents.

d) Strengthen the manufacturing and quality assurance functions


- We will newly establish the Reagent Manufacturing Management Department and the Manufacturing Information Management Department within the Manufacturing Management Division to prepare strategies related to global reagent production, and heighten cooperation within the Group, thereby accelerating high-quality production.
- We will newly establish the Quality Control Department within the Instrument Production Division to strengthen the quality control function related to instrument manufacturing.
- We will establish the PSI Department within the SCM Division to prepare highly precise production plans based on global instrument and reagent demand forecasts.

(PSI: production, sales and inventory)


e) Reconfigure the global sales and service functions

- We will newly establish the JEA Region Division to integrate the sales and service functions for the Japan and East Asia (South Korea, Taiwan and Mongolia) region.
- We will newly establish the Global Support Division to integrate the global service and support function and the overseas sales and service support function.

### New Organizational Structure



### Previous Organizational Structure



## 2. Personnel Changes and Appointments

### (1) Appointments of Senior Executive Officers (Promotions)

Name	New Position	Current Position
Kaoru Asano	Member of the Managing Board and Senior Executive Officer Senior Managing Director	Member of the Managing Board and Senior Executive Officer Managing Director
Kenji Tachibana	Member of the Managing Board and Senior Executive Officer Senior Managing Director	Member of the Managing Board and Senior Executive Officer Managing Director
Junzo Yamamoto	Senior Executive Officer Managing Director	Senior Executive Officer
Iwane Matsui	Senior Executive Officer	Executive Officer
Hiroshi Kanda	Senior Executive Officer	Executive Officer

### (2) Appointments of Executive Officers (Newly Appointed)

Name	New Position	Current Position
Peng Zuo Hui	Executive Officer	President and CEO, Sysmex Shanghai Ltd.
Tomokazu Yoshida	Executive Officer	Executive Vice President of Central Research Laboratories
Kensuke Iizuka	Executive Officer	Executive Vice President of Corporate Business Planning Office

### (3) Retirement of Executive Officers (Completion of Contract Term)

Name	New Position	Current Position
Masayoshi Hayashi	Member of the Managing Board	Member of the Managing Board and Senior Executive Officer Senior Managing Director
Koji Tamura	Member of the Managing Board	Member of the Managing Board and Senior Executive Officer Managing Director
Michiaki Ishida	1	Senior Executive Officer
Takashi Goda	2	Senior Executive Officer

1 After retirement of the current position, he will become Adviser of Sysmex Corporation.

2 After retirement of the current position, he will become President and CEO of Sysmex CNA Co., Ltd.

**(4) Changes in Operating and Functional Changes of Executive Officers**

Name	New Position	Current Position
<p>Yukio Nakajima</p>	<p>Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Business Planning Div. Corporate Communication Div. Corporate Business Administration Div. Human Resources Div. General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd. Sysmex Harmony Co., Ltd.*</p>	<p>Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Corporate Communication Div. Corporate Business Administration Div. Human Resources &amp; General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd.</p>
<p>Kaoru Asano</p>	<p>Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Technology Strategy Div. Central Research Laboratories Technology Development Div. Intellectual Property Div. LS Business Div. Clinical Innovation Div. MR Business Development Div. Medicaroid Corporation Sysmex Engineering Co., Ltd. RIKEN GENESIS CO., LTD. Sysmex Inostics GmbH Vice President of Medicaroid Corporation Director of RIKEN GENESIS CO., LTD.</p>	<p>Member of the Managing Board and Senior Executive Officer Managing Director In charge of; R&amp;D Strategic Planning Div. Central Research Laboratories Technology Development Div. Medicaroid Corporation Sysmex Engineering Co., Ltd. RIKEN GENESIS CO., LTD. Vice President of Medicaroid Corporation Director of RIKEN GENESIS CO., LTD.</p>

Name	New Position	Current Position
Kenji Tachibana	Member of the Managing Board and Senior Executive Officer Senior Managing Director In charge of; Business Strategy Development Div. HU Business Development Div. ICH Business Development Div. Engineering 1 Div. Engineering 2 Div. Sysmex Partec GmbH HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd.	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; Corporate Business Planning Div. Business Strategy Development Div.
Kazuya Obe	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; JEA Region Div. Sales and Marketing East / Japan Div. Sales and Marketing West / Japan Div. Global Support Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd. Sysmex America, Inc. Sysmex Europe GmbH Sysmex Shanghai Ltd. Sysmex Asia Pacific Pte Ltd. Sysmex Korea Co., Ltd. Sysmex Taiwan Co., Ltd.	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; International Business Management Div. Sysmex America, Inc. Sysmex Europe GmbH Sysmex Shanghai Ltd. Sysmex Asia Pacific Pte Ltd. Sysmex Korea Co., Ltd. Sysmex Taiwan Co., Ltd.
Mitsuru Watanabe	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; Scientific Affairs Div. Bio-Diagnostic Reagent Technology Center	Member of the Managing Board and Senior Executive Officer Managing Director In charge of; HU Business Unit Hematology Product Engineering Div. UB Product Engineering Div. Business Management Dept.

Name	New Position	Current Position
Junzo Yamamoto	Senior Executive Officer Managing Director In charge of; Manufacturing Management Div. Instrument Production Div. SCM Div. Sysmex International Reagents Co., Ltd. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd.	Senior Executive Officer In charge of; Manufacturing Management Div. Instrument Production Div. SCM Div. Sysmex RA Co., Ltd. Sysmex Medica Co., Ltd.
Iwane Matsui	Senior Executive Officer Deputy In charge of; JEA Region Div. Sales and Marketing East / Japan Div. Sales and Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd. Sysmex Korea Co., Ltd. Sysmex Taiwan Co., Ltd. Representative of Tokyo Office	Executive Officer In charge of; Business Management (Japan) Div. Sales & Marketing East / Japan Div. Sales & Marketing West / Japan Div. Sysmex TMC Co., Ltd Sysmex CNA Co., Ltd. Sysmex bioMérieux Co., Ltd. Representative of Tokyo Office
Hiroshi Kanda	Senior Executive Officer Deputy In charge of; HU Business Development Div. ICH Business Development Div. HYPHEN BioMed, SAS Sysmex Wuxi Co., Ltd. Executive Vice President of ICH Business Development Div.	Executive Officer Executive Vice President of ICH Business Unit Hemostasis Product Engineering Div.
Yukio Hamaguchi	Executive Officer President and CEO, Sysmex International Reagents Co., Ltd.	Executive Officer President and CEO, Sysmex International Reagents Co., Ltd.
Keiji Fujimoto	Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div.	Executive Officer In charge of; Regulatory Affairs & Quality Assurance Div. Scientific Affairs Div. Customer Support Div.
Ikuo Otani	Executive Officer Deputy In charge of; Engineering 1 Div. Engineering 2 Div.	Executive Officer Executive Vice President of Human Resources & General Affairs Div.

Name	New Position	Current Position
Hiroshi Nagao	Executive Officer Executive Vice President of Corporate Business Administration Div.	Executive Officer Executive Vice President of Corporate Business Administration Div.
John Kershaw	Executive Officer Chairman, Sysmex America, Inc. Deputy In charge of; Business Strategy Development Div. HU Business Development Div. ICH Business Development Div. Engineering 1 Div. Engineering 2 Div.	Executive Officer President and CEO, Sysmex America, Inc.
Juergen Schulze	Executive Officer President and CEO, Sysmex Europe GmbH	Executive Officer President and CEO, Sysmex Europe GmbH
Mamoru Kubota	Executive Officer Executive Vice President of LS Business Div. President and CEO, Sysmex Inostics GmbH President and CEO, Sysmex Inostics, Inc.	Executive Officer Executive Vice President of LS Business Unit Life Science Product Engineering Div. President and CEO, Sysmex Inostics GmbH President and CEO, Sysmex Inostics, Inc.
Peng Zuo Hui	Executive Officer President and CEO, Sysmex Shanghai Ltd.	President and CEO, Sysmex Shanghai Ltd.
Tomokazu Yoshida	Executive Officer Executive Vice President of Central Research Laboratories, MR Business Development Div. Director of Medicaroid Corporation	Executive Vice President of Central Research Laboratories Director of Medicaroid Corporation
Kensuke Iizuka	Executive Officer Deputy In charge of; Corporate Business Planning Div. Corporate Communication Div. Human Resources Div. General Affairs Div. Corporate Executive Office Sysmex Business Support Co., Ltd. Sysmex Harmony Co., Ltd.*	Executive Vice President of Corporate Business Planning Div.

\*Sysmex Harmony Co., Ltd. is scheduled for establishment on April 3, 2017.